Skip to main
PASG

PASSAGE BIO (PASG) Stock Forecast & Price Target

PASSAGE BIO (PASG) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 20%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

Passage Bio is poised for success as their pipeline, including lead candidate PBFT02, targets critical underlying pathologies in neurodegenerative diseases. While their focus on one-time gene therapies is a promising approach, the regulatory hurdles for these types of treatments should not be overlooked, as evidenced by Eli Lilly's recent program discontinuation due to lack of compelling efficacy. Despite this, Passage Bio's strong financial position with $302.7 million in cash and investments as of September 30, 2021, provides the necessary resources to potentially overcome any regulatory challenges.

Bears say

Passage Bio is a clinical-stage genetic medicines company with a single reportable segment focused on developing and advancing genetic medicines targeting neurodegenerative diseases. While the company has a robust pipeline and strong biomarker data, their limited resources and the challenges faced by all gene therapy programs make their planned registrational study for their lead program, PBFT02, nearly impossible. In addition, their focus on a disease with no treatment options may not be enough to convince the FDA to provide a flexible regulatory pathway.

PASSAGE BIO (PASG) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 20% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PASSAGE BIO and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PASSAGE BIO (PASG) Forecast

Analysts have given PASSAGE BIO (PASG) a Buy based on their latest research and market trends.

According to 5 analysts, PASSAGE BIO (PASG) has a Buy consensus rating as of Aug 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PASSAGE BIO (PASG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.